Stock events for EXACT Sciences Corp. (EXAS)
In the past six months, Exact Sciences' stock has been impacted by several significant events. Stockholders approved the acquisition by Abbott Laboratories. The company announced record fourth-quarter and full-year 2025 results, with strong revenue growth but an earnings miss. Analyst sentiment cooled following the earnings miss, leading to downgrades. Exact Sciences applauded the passage of legislation establishing a Medicare coverage pathway for Multi-Cancer Early Detection Tests.
Demand Seasonality affecting EXACT Sciences Corp.’s stock price
While detailed information on demand seasonality is limited, Exact Sciences' Q1 guidance was lower than expected due to seasonal trends. Analysis of EXAS stock performance indicates some seasonality, with April having the highest probability of a positive return. The company's reliance on promotional marketing for Cologuard demand raises concerns about sustainability.
Overview of EXACT Sciences Corp.’s business
EXACT Sciences Corp., based in Madison, Wisconsin, operates in the healthcare sector, focusing on cancer detection technologies. The company offers cancer screening and diagnostic tests, including Cologuard, a non-invasive stool-based DNA screening test for colorectal cancer, and the Oncotype DX portfolio, tissue-based genomic tests for breast and colon cancer treatment decisions. They are developing new technologies like Cancerguard, a multi-cancer early detection blood test, and Oncodetect, an MRD test.
EXAS’s Geographic footprint
EXACT Sciences Corp. operates in the United States and internationally. Tests are processed in CLIA-certified, CAP-accredited laboratories in Wisconsin, California, Arizona, and Washington, with Cologuard components manufactured in Wisconsin. The company has international offices and R&D labs in various locations, including Baar, London, Milan, Munich, Planegg, Oxford, Paris, Tokyo, and Warsaw, with a testing site in Trier.
EXAS Corporate Image Assessment
EXACT Sciences has maintained a positive brand reputation. The company earned the Gallup Exceptional Workplace Award for the third consecutive year. Its innovative product portfolio, including Cologuard and the Oncotype DX suite, contributes to its strong brand recognition.
Ownership
EXACT Sciences Corp. has a mixed ownership structure. Institutional investors hold a significant portion of the company's stock, with major holders including Vanguard Group Inc. and BlackRock, Inc. Insiders own approximately 1.20% of the company's stock. Public companies and individual/retail investors hold approximately 13.15% to 42.79% of the stock.
